Related Experiment Video
Updated: May 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information
Takashi Funatogawa1, Kazuma Mii1, Kazuki Kojima1
1Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan.
Objectives:
The 2023 EULAR guidelines for systemic sclerosis (SSc) recommend biologics (rituximab, tocilizumab), mycophenolate mofetil (MMF), and nintedanib in addition to cyclophosphamide for interstitial lung disease (ILD). This study investigated recent actual use of these drugs in Japan.
Methods:
We analysed data from a Japanese hospital claims database (2020-3), identifying patients with SSc disease codes (ICD-10 M34.x) and/or ILD codes. Patients with coexisting autoimmune disease codes were also included.
Results:
Of 14,522 SSc patients, 2080 (14.3%) received small-molecule drugs and 618 (4.3%) received biologics. For SSc, common first small-molecule drugs were methotrexate (24.2%), nintedanib (19.5%), tacrolimus (17.9%), and MMF (16.8%); common first biologics were rituximab (44.2%) and tocilizumab (29.1%). Of 4890 SSc-ILD patients, 1081 (22.1%) received small-molecule drugs and 282 (5.8%) received biologics. For SSc-ILD, common first small-molecule drugs were nintedanib (30.8%), tacrolimus (20.9%), and MMF (18.3%); common first biologics were rituximab (51.8%) and tocilizumab (25.2%). Rituximab showed the greatest increase in use for both SSc and SSc-ILD between 2020 and 2023. Common subsequent treatments following rituximab or intravenous cyclophosphamide (which are typically administered for a limited duration) were nintedanib, MMF, and rituximab.
Conclusions:
Recent actual drug use in Japan has been aligning increasingly closely with the EULAR recommendations.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

